Neuralstem Gains on Stem Cell Therapy for Paralyzed Rats

Neuralstem, a biotechnology company with no approved products, gained the most ever after saying its stem cell treatment restored paralyzed rats’ ability to move in an early study. Neuralstem rose 38 percent to $1.38 at the close of trading in New York, its largest single-day gain since the shares first started trading in December 2006.
Bloomberg